FibroGen Inc (FGEN)
0.3954
+0.01
(+2.12%)
USD |
NASDAQ |
Nov 22, 16:00
0.40
0.00 (0.00%)
Pre-Market: 20:00
FibroGen Cash from Operations (Quarterly): -8.376M for Sept. 30, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -8.376M |
| June 30, 2024 | -39.87M |
| March 31, 2024 | -59.29M |
| December 31, 2023 | -18.32M |
| September 30, 2023 | -84.54M |
| June 30, 2023 | -110.57M |
| March 31, 2023 | -101.59M |
| December 31, 2022 | -52.51M |
| September 30, 2022 | -51.88M |
| June 30, 2022 | -33.06M |
| March 31, 2022 | -8.476M |
| December 31, 2021 | -54.96M |
| September 30, 2021 | 44.26M |
| June 30, 2021 | -26.54M |
| March 31, 2021 | -44.98M |
| December 31, 2020 | -7.228M |
| September 30, 2020 | -1.349M |
| June 30, 2020 | 149.66M |
| March 31, 2020 | -59.49M |
| December 31, 2019 | -45.05M |
| September 30, 2019 | -27.48M |
| June 30, 2019 | -28.65M |
| Date | Value |
|---|---|
| March 31, 2019 | 22.48M |
| December 31, 2018 | -17.46M |
| September 30, 2018 | 8.248M |
| June 30, 2018 | -34.96M |
| March 31, 2018 | -31.96M |
| December 31, 2017 | -1.186M |
| September 30, 2017 | -18.43M |
| June 30, 2017 | -19.76M |
| March 31, 2017 | -27.14M |
| December 31, 2016 | -18.54M |
| September 30, 2016 | -1.767M |
| June 30, 2016 | 44.68M |
| March 31, 2016 | -17.26M |
| December 31, 2015 | -39.30M |
| September 30, 2015 | -38.12M |
| June 30, 2015 | 101.05M |
| March 31, 2015 | -42.19M |
| December 31, 2014 | -23.76M |
| September 30, 2014 | -31.06M |
| June 30, 2014 | 92.76M |
| March 31, 2014 | -15.52M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-110.57M
Minimum
Jun 2023
149.66M
Maximum
Jun 2020
-30.71M
Average
-42.43M
Median
Cash from Operations (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 221.48M |
| Arbutus Biopharma Corp | -20.74M |
| GlycoMimetics Inc | -7.994M |
| Cidara Therapeutics Inc | -36.70M |
| Cue Biopharma Inc | -7.527M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 0.755M |
| Cash from Financing (Quarterly) | -0.127M |
| Free Cash Flow | -126.23M |
| Free Cash Flow Per Share (Quarterly) | -0.0841 |
| Free Cash Flow to Equity (Quarterly) | -8.759M |
| Free Cash Flow to Firm (Quarterly) | -7.265M |
| Free Cash Flow Yield | -321.0% |